7QEL

Structure of the mouse 8-oxoguanine DNA Glycosylase mOGG1 in complex with ligand TH011247


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 
    0.295 (Depositor), 0.290 (DCC) 
  • R-Value Work: 
    0.252 (Depositor), 0.250 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Virtual fragment screening for DNA repair inhibitors in vast chemical space.

Luttens, A.Vo, D.D.Scaletti, E.R.Wiita, E.Almlof, I.Wallner, O.Davies, J.Kosenina, S.Meng, L.Long, M.Mortusewicz, O.Masuyer, G.Ballante, F.Michel, M.Homan, E.Scobie, M.Kalderen, C.Warpman Berglund, U.Tarnovskiy, A.V.Radchenko, D.S.Moroz, Y.S.Kihlberg, J.Stenmark, P.Helleday, T.Carlsson, J.

(2025) Nat Commun 16: 1741-1741

  • DOI: https://doi.org/10.1038/s41467-025-56893-9
  • Primary Citation of Related Structures:  
    7QEL, 7Z3Y, 7Z5B, 7Z5R, 7ZC7, 7ZG3, 8CEX, 8CEY

  • PubMed Abstract: 

    Fragment-based screening can catalyze drug discovery by identifying novel scaffolds, but this approach is limited by the small chemical libraries studied by biophysical experiments and the challenging optimization process. To expand the explored chemical space, we employ structure-based docking to evaluate orders-of-magnitude larger libraries than those used in traditional fragment screening. We computationally dock a set of 14 million fragments to 8-oxoguanine DNA glycosylase (OGG1), a difficult drug target involved in cancer and inflammation, and evaluate 29 highly ranked compounds experimentally. Four of these bind to OGG1 and X-ray crystallography confirms the binding modes predicted by docking. Furthermore, we show how fragment elaboration using searches among billions of readily synthesizable compounds identifies submicromolar inhibitors with anti-inflammatory and anti-cancer effects in cells. Comparisons of virtual screening strategies to explore a chemical space of 10 22 compounds illustrate that fragment-based design enables enumeration of all molecules relevant for inhibitor discovery. Virtual fragment screening is hence a highly efficient strategy for navigating the rapidly growing combinatorial libraries and can serve as a powerful tool to accelerate drug discovery efforts for challenging therapeutic targets.


  • Organizational Affiliation

    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Box 596, SE-751 24, Uppsala, Sweden.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
N-glycosylase/DNA lyaseA [auth AAA],
B [auth BBB],
C [auth CCC]
318Mus musculusMutation(s): 0 
Gene Names: Ogg1
EC: 3.2.2 (PDB Primary Data), 4.2.99.18 (PDB Primary Data)
UniProt
Find proteins for O08760 (Mus musculus)
Explore O08760 
Go to UniProtKB:  O08760
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO08760
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free:  0.295 (Depositor), 0.290 (DCC) 
  • R-Value Work:  0.252 (Depositor), 0.250 (DCC) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 81.35α = 90
b = 81.397β = 90
c = 168.405γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
DIALSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Swedish Research CouncilSweden--
CancerfondenSweden--

Revision History  (Full details and data files)

  • Version 1.0: 2022-12-14
    Type: Initial release
  • Version 1.1: 2024-01-31
    Changes: Data collection, Refinement description
  • Version 1.2: 2025-03-05
    Changes: Database references, Structure summary